Background: Primary Sjö gren's syndrome (pSS) is a commonly occurring multisystem autoimmune condition affecting around 1% of the population. Fatigue is a prominent and disabling feature of pSS and current treatment avenues are aimed at other manifestations of the condition. Interest in fatigue is now increasing, and studies are being designed to investigate treatment directed against fatigue in pSS. Biologics are also being widely used, with growing interest in B cell depleting therapy such as rituximab, as B cells play a prominent role in the pathogenesis. The aim of this systematic review is to summarize the existing therapies and determine how effective they are in reducing fatigue, and to conclude whether a superior effect of B cell directed therapies exist. Methods: The Medline and Embase databases were searched using the terms SS and fatigue between 1946 and 2013. The population included were adults over the age of 18, who met the AmericanEuropean Consensus Criteria for pSS. The intervention was receiving biologic or pharmacological therapy. The outcome measured was an improvement in fatigue scores from baseline, using visual analogue scales, or the Multidimensional Fatigue Inventory. Randomized controlled trials [RCTs] and prospective studies that assessed improvement in fatigue as a primary or secondary outcome were included. Retrospective studies, case reports, and conference abstracts were excluded. Results: The search yielded 8 suitable randomized controlled trials and 7 prospective studies. Two RCTs and three prospective studies involved rituximab, and all showed statistically significant improvements from baseline in fatigue scores. Small prospective studies of epratuzumab, LEF, infliximab and zidovudine also demonstrated statistically significant improvements in fatigue scores. RCTs using dehydroepiandrosterone showed significant improvements in fatigue scores, but also showed a placebo effect. Studies of HCQ, anakinra vs placebo, low dose doxycycline and a large RCT of infliximab did not produce significant results. Conclusion: This is the first systematic review of treatments of fatigue in pSS. Overall there is a low level of evidence for treating fatigue in pSS, and studies are underpowered. There is no single effective treatment for fatigue in pSS, but the data suggest a promising role of B cell directed therapies. Fatigue is measured by a variety of scoring systems, which reflects multifactorial contributors, and the placebo effect found implicates a psychological component driving or maintaining fatigue. Future prospects include larger trials with more participants to study the role of B cells, some of which are underway. Studies should also be aimed at a multidimensional approach compared with single therapeutic agents, as the treatment of fatigue should include psychological input, and patients are likely to benefit from combined therapies. Background: People with primary SS (PSS) suffer with a range of symptoms including dryness, pain, fatigue, autonomic dysfunction, low mood and functional impairment. Non-pharmacological interventions such as physiotherapy, occupational therapy, complimentary therapies, devices and psychotherapy aim to relieve symptoms and improve function. We conducted a systematic review of these interventions' efficacy and registered the protocol in advance with PROSPERO (CRD42013004997). Methods: Search strategy: Databases were searched from inception to July 2013 with a pre-defined list of search terms: Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Medline, Embase, PsychINFO, Cinahl, AMED, CCTR, WHO ICTRP, UCLRN and the National Research Register Archive and reviewed the reference lists of included studies. Selection criteria: Studies were included if they were randomized controlled trials (RCTs) of any non-pharmacological interventions for adults with PSS. Any comparator was allowed. Titles and abstracts of studies were considered according to the inclusion/exclusion criteria. Full texts were reviewed independently by two authors for inclusion or exclusion. Data abstraction: Two review authors separately extracted the data the included studies on a standardized form. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Outcomes fell within the main domains addressed by the World Health Organisation International Classification of Functioning. Results: 996 studies were identified of which 17 full text articles were screened and 5 studies were included in this review with a total of 130 participants randomized. The included studies investigated effectiveness of an oral lubricating device for dry mouth, acupuncture for dry mouth, lacrimal punctum plugs for dry eyes and psychodynamic group therapy for coping with symptoms. Frost showed that salivary flow and speed of speech improved with the oral lubricating device but this small study (n ¼ 29) was at high risk of bias. Mansour investigated punctum plugs but had no extractable data whereas Qui compared punctum plugs to artificial tears reported improvements in most outcomes in both groups, but significantly better results in the punctum plugs group on tear volume and stabilizing tear film. The Qui study was of good quality but too small (n ¼ 42) for these results to be regarded as definitive. Poulson showed no advantage of psychodynamic therapy over the untreated control group in a small (n ¼ 18) poor quality study. Conclusion: Although one study showed punctum plugs to be better at improving dry eyes it was too small for the findings to be conclusive. Therefore overall we identified no evidence to support any nonpharmacological interventions to improve PSS. The area needs good quality large RCTs that are reported according to CONSORT guidelines. 
